This is a multi-center, randomized, double-blind, active-controlled, non-inferiority, phase 3 study to evaluate the efficacy and safety of MCT-SR in patients with gastritis.

To contribute greater treatment compliance and patient convenience, the rebamipide SR formulation has been developed.

Inclusion Criteria:

• Adult males and females aged ≥19 and <75 years
• Patients diagnosed with acute or chronic gastritis by gastroscopy with at least 1 erosion confirmed by gastroscopy within 7 days prior to the first dose of the Investigational Product(IP)

Exclusion Criteria:

• Patients ineligible for gastroscopy
• Patients who took other drugs for treating gastritis within 2 weeks prior to the first dose of the IP.
• Patients who have to continue taking drugs that may induce gastritis
• Other clinically significant medical or psychiatric findings that the investigator considers inappropriate for the study